2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04302870 (ClinicalTrials.gov) | February 27, 2020 | 4/3/2020 | Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial | Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial | Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Drug: Memantine Hydrochloride Oral Solution;Drug: Trazodone Hydrochloride oral solution;Drug: Placebo oral solution | University of Edinburgh | University College, London;University of Warwick;NHS Lothian | Recruiting | 18 Years | N/A | All | 750 | Phase 2/Phase 3 | United Kingdom |
| 2 | NCT02118727 (ClinicalTrials.gov) | November 7, 2018 | 15/4/2014 | Therapy in Amyotrophic Lateral Sclerosis (TAME) | Multi-centered Double Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Memantine at 20 mg BID in Patients With ALS | Amyotrophic Lateral Sclerosis;Frontal Temporal Dementia | Drug: Memantine;Drug: Placebo (for Memantine) | University of Kansas Medical Center | University of Missouri-Columbia | Completed | 18 Years | 85 Years | All | 90 | Phase 2 | United States |
| 3 | EUCTR2007-002117-39-ES (EUCTR) | 31/01/2008 | 12/02/2008 | MEMANTINA (Ebixa X) PARA LA DISCAPACIDAD FUNCIONAL EN LA ESCLEROSIS LATERAL AMIOTRÓFICAMEMANTINE (Ebixa R) FOR FUNCTIONAL DISABILITY IN AMYOTROPHIC LATERAL SCLEROSIS . - MEDALS | MEMANTINA (Ebixa X) PARA LA DISCAPACIDAD FUNCIONAL EN LA ESCLEROSIS LATERAL AMIOTRÓFICAMEMANTINE (Ebixa R) FOR FUNCTIONAL DISABILITY IN AMYOTROPHIC LATERAL SCLEROSIS . - MEDALS | Esclerosis Lateral AmiotroficaAmyotrophic lateral Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis | Trade Name: EBIXA INN or Proposed INN: MEMANTINE HYDROCHLORIDE | Jorge Matias-Guiu Guia | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 140 | Spain | |||
| 4 | NCT00409721 (ClinicalTrials.gov) | March 2007 | 8/12/2006 | The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS) | A Randomized, Double-blind, Dose Ranging Study to Determine the Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Patients With ALS | Amyotrophic Lateral Sclerosis | Drug: Memantine | University of Alberta | ALS Association | Completed | 18 Years | 80 Years | Both | 42 | Phase 2 | Canada |
| 5 | NCT00353665 (ClinicalTrials.gov) | July 2005 | 18/7/2006 | Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) | Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Memantine (Ebixa);Drug: riluzole;Drug: Placebo | University of Lisbon | H. Lundbeck A/S | Completed | 20 Years | 75 Years | Both | 63 | Phase 2/Phase 3 | Portugal |
| 6 | NCT01020331 (ClinicalTrials.gov) | June 2005 | 20/11/2009 | Memantine Therapy in Amyotrophic Lateral Sclerosis | Phase IIA Open Label Trial of Memantine in Combination With Riluzole (Customary Care) for the Treatment of ALS | Amyotrophic Lateral Sclerosis | Drug: Memantine | Phoenix Neurological Associates, LTD | Forest Laboratories | Completed | 18 Years | 85 Years | Both | 20 | Phase 2 | United States |